The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Researchers take a step towards improved antibody therapy

Photo of injection.
Antibody-based drugs in high concentrations often become so viscous that they are difficult to inject. Photo: Unsplash

Antibody-based drugs often become too thick to be injected at high concentrations. Now, new research can explain why this happens—knowledge that could eventually lead to easily injectable medications.

Antibody-based drugs are currently used to treat cancer, autoimmune diseases, and inflammatory conditions. To be administered as a simple injection under the skin, they need to be concentrated, but at high concentrations, they often become too thick to handle. This affects both how accessible a treatment is, as well as the patient’s discomfort.

By using advanced computer simulations, the researchers were able to show that the increased viscosity (a term describing how easily or thickly a substance flows) is due to antibodies in concentrated solutions forming short-lived, strongly charge-driven structures. These temporary formations cause the solution to "thicken."

"We were surprised that models previously used to describe the structure of antibody solutions couldn't predict these dynamics. It's clear that electrical charges play a crucial role in understanding the true properties," explains Fabrizio Camerin, chemistry researcher at Lund University. 

Unlike more basic models, the study shows that one must consider both the complex charge distribution of the antibodies and the surrounding ions in the solution, to accurately reproduce experimental results.

The findings pave the way for new methods of predicting how different antibodies will behave at high concentrations. This could provide valuable guidance for pharmaceutical companies in creating formulations that remain stable yet easy to inject.

"By understanding the mechanism behind viscous antibody solutions, we can contribute to better treatment strategies and improved quality of life for patients," concludes Fabrizio Camerin.

The study is published in the scientific journal Proceedings of the National Academy of Sciences, PNAS: ”Electrostatics and viscosity are strongly linked in concentrated antibody solutions”

Contact

Fabrizio Camerin

Postdoctoral fellow at Physical Chemistry
fabrizio [dot] camerin [at] fkem1 [dot] lu [dot] se (fabrizio[dot]camerin[at]fkem1[dot]lu[dot]se)

About the study:

The work is the result of a long-term collaboration between Emanuela Zaccarelli's research group in Rome (CNR-ISC and Sapienza University) and the research groups led by Anna Stradner and Peter Schurtenberger at the Department of Physical Chemistry at Lund University. The project has also benefited greatly from the research program “Antibodies in Solution Research Program” at the LINXS Institute of Advanced Neutron and X-ray Science.